Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.50 -0.7%	$187.37	$163.63 ▼ $218.66	$334.34B	0.48	6.25 million shs	3.71 million shs
BMY Bristol Myers Squibb	$47.02 -1.3%	$47.73	$39.35 ▼ $63.33	$95.49B	0.36	12.88 million shs	7.02 million shs
GSK GSK	$38.26 -0.6%	$39.00	$31.72 ▼ $44.67	$78.17B	0.5	4.93 million shs	3.00 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	+4.19%	+1.17%	+1.57%	+15.66%
BMY Bristol Myers Squibb	0.00%	+1.45%	-2.07%	-15.01%	+17.36%
GSK GSK	0.00%	-0.74%	-6.29%	+4.84%	-0.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9079 of 5 stars	3.4	5.0	3.3	3.9	2.8	1.7	1.3
BMY Bristol Myers Squibb	4.9285 of 5 stars	3.2	3.0	4.2	4.0	3.4	3.3	1.3
GSK GSK	2.3635 of 5 stars	1.1	4.0	2.5	0.0	2.6	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	11.50% Upside
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.36% Upside
GSK GSK	2.10	Hold	$37.38	-2.31% Downside

Current Analyst Ratings Breakdown

Latest ABBV, BMY, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.94	$14.94 per share	12.68	$1.90 per share	99.74
BMY Bristol Myers Squibb	$48.30B	1.98	$5.90 per share	7.97	$8.08 per share	5.82
GSK GSK	$40.10B	1.95	$5.59 per share	6.84	$8.07 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	80.64	13.56	1.26	7.31%	412.03%	13.11%	7/31/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.61	7.72	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.72	8.23	1.53	9.89%	48.82%	11.15%	7/30/2025 (Estimated)

Latest ABBV, BMY, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.46%	N/A	279.15%	53 Years
BMY Bristol Myers Squibb	$2.48	5.27%	N/A	92.88%	17 Years
GSK GSK	$1.69	4.42%	N/A	87.11%	N/A

Latest ABBV, BMY, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
BMY Bristol Myers Squibb	2.65	1.28	1.17
GSK GSK	1.21	0.87	0.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol Myers Squibb	76.41%
GSK GSK	15.74%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol Myers Squibb	0.09%
GSK GSK	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable

ABBV, BMY, and GSK Headlines

Recent News About These Companies

GSK’s Promising IPF Drug Study: A Potential Game Changer for Investors

July 4 at 12:13 PM | tipranks.com

Aurora Private Wealth Inc. Makes New $692,000 Investment in GSK PLC Sponsored ADR (NYSE:GSK)

July 4 at 6:35 AM | marketbeat.com

GSK PLC Sponsored ADR (NYSE:GSK) Receives $37.38 Consensus PT from Analysts

July 4 at 2:23 AM | americanbankingnews.com

GSK’s New COPD Study: A Potential Game-Changer for Respiratory Treatment

July 3 at 1:14 PM | tipranks.com

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

July 3 at 1:11 PM | zacks.com

GSK counts on Blenrep rebound to drive Â£40bn sales goal

July 3 at 10:02 AM | proactiveinvestors.co.uk

GSK counts on Blenrep rebound to drive £40bn sales goal

July 3 at 9:45 AM | proactiveinvestors.co.uk

Ameritas Advisory Services LLC Sells 17,908 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

July 3 at 4:47 AM | marketbeat.com

Stock Traders Purchase Large Volume of GSK Put Options (NYSE:GSK)

July 3 at 2:13 AM | americanbankingnews.com

GSK’s New IPF Drug Study: Potential Market Impact

July 2 at 12:41 PM | tipranks.com

‘Real world’ COPD trial gives GSK a dose of reality

July 2 at 12:39 PM | pharmaphorum.comP

Yelin Lapidot Holdings Management Ltd. Raises Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

July 2 at 10:02 AM | marketbeat.com

Miller Howard Investments Inc. NY Acquires 955,891 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

July 2 at 9:52 AM | marketbeat.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

July 2 at 9:51 AM | zacks.com

Gilead Eyes HIV Market Domination With Twice-Yearly Yeztugo as GSK Trails

July 2 at 7:37 AM | biospace.comB

Investors Buy Large Volume of Put Options on GSK (NYSE:GSK)

July 1, 2025 | marketbeat.com

9,644 Shares in GSK PLC Sponsored ADR (NYSE:GSK) Acquired by Diversified Trust Co

July 1, 2025 | marketbeat.com

GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of "Hold" by Brokerages

July 1, 2025 | marketbeat.com

Moderna says flu shot more effective than rival GSK in late-stage study

June 30, 2025 | msn.com

GSK’s Innovative Hepatitis B Treatment Study: Market Implications and Progress

June 30, 2025 | tipranks.com

GSK PLC Sponsored ADR (NYSE:GSK) Shares Acquired by Argent Advisors Inc.

June 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABBV, BMY, and GSK Company Descriptions

AbbVie NYSE:ABBV

$189.50 -1.25 (-0.66%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$188.90 -0.60 (-0.32%)

As of 07/3/2025 04:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$47.02 -0.62 (-1.29%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$47.02 0.00 (0.00%)

As of 07/3/2025 04:57 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK NYSE:GSK

$38.26 -0.25 (-0.65%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$38.28 +0.02 (+0.04%)

As of 07/3/2025 04:59 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time